Advanced Accelerator Applications (NASDAQ:AAAP) is an innovative radiopharmaceutical company developing, producing and commercializing molecular nuclear medicine theragnostics.
AAA is at the forefront of developing predictive, preventive and personalized tools and procedures that have the potential to radically transform healthcare. Our path to accomplishing this goal is by merging therapeutic and diagnostic approaches to advance early detection, treatment, and monitoring of diseases, improving patient management.
AAA is developing a pipeline of theragnostic pairings for oncology indications. The company’s theragnostic platform involves radiolabeling a targeting molecule with either gallium Ga 68 for diagnostic use, or lutetium Lu 177 for therapy.
AAA’s first theragnostic pairing addresses neuroendocrine tumors, an orphan indication. The diagnostic part of this pairing is marketed as NETSPOT® in the US or SomaKit TOC™ in Europe. The therapeutic part, USAN: lutetium Lu 177 dotatate/INN: lutetium (177Lu) oxodotreotide (Lutathera®), is approved for use in Europe, and currently under review with the US Food and Drug Administration. Additional pairings in development target Gastrointestinal Stromal Tumors (GIST), and prostate and breast cancer.
AAA is a leader in the production and commercialization of molecular nuclear diagnostic radiopharmaceuticals for Positron Emission Tomography (PET) and Single-Photon Emission Computed Tomography (SPECT). The Company currently markets 9 products (8 in Europe and 1 in the US), mainly used for diagnosis in clinical oncology, cardiology, neurology and infectious/inflammatory diseases.
AAA currently has 20 production and research & development facilities that manufacture both diagnostic and therapeutic Molecular Nuclear Medicine products, and over 600 employees in 13 countries (Belgium, Canada, France, Germany, Israel, Italy, the Netherlands, Poland, Portugal, Spain, Switzerland, the UK and the US).